Sam Brusco, Associate Editor04.06.22
Endovascular Engineering (E2), a developer of next-gen thrombectomy devices for deep vein thrombosis (DVT) and pulmonary embolism (PE) closed $15 million Series A1 financing yesterday. Co-led by Santé Ventures and Cordis, E2 will use the proceeds to bring its thrombectomy platform through initial clinical evaluation.
E2 founder and chief scientific officer Dr. Luis Savastano developed the thrombectomy system alongside the Menlo Park, Calif.-based medical device incubator Inventure Group.
"With the close of this funding we will continue the journey from concept to clinical use,” Dr. Savastano told the press. We are confident our vision of single-pass peripheral thrombectomy procedures will be realized with the introduction of E2's thrombectomy solution."
"The E2 team is thrilled to welcome our new investment partners to further the pursuit of healthcare solutions that matter,” added E2 CEO Mike Rosenthal. “We share a pioneering spirit dedicated to serving patients and physicians in the underserved peripheral indications."
"There is a large, unmet medical need for an efficient and easy to use thrombectomy solution in the peripheral space," said Dr. James Eadie, managing director at Santé Ventures and E2 board member. "E2's platform technology is elegant, procedurally focused, and backed by a strong team of medical device entrepreneurs and engineers."
E2 founder and chief scientific officer Dr. Luis Savastano developed the thrombectomy system alongside the Menlo Park, Calif.-based medical device incubator Inventure Group.
"With the close of this funding we will continue the journey from concept to clinical use,” Dr. Savastano told the press. We are confident our vision of single-pass peripheral thrombectomy procedures will be realized with the introduction of E2's thrombectomy solution."
"The E2 team is thrilled to welcome our new investment partners to further the pursuit of healthcare solutions that matter,” added E2 CEO Mike Rosenthal. “We share a pioneering spirit dedicated to serving patients and physicians in the underserved peripheral indications."
"There is a large, unmet medical need for an efficient and easy to use thrombectomy solution in the peripheral space," said Dr. James Eadie, managing director at Santé Ventures and E2 board member. "E2's platform technology is elegant, procedurally focused, and backed by a strong team of medical device entrepreneurs and engineers."